TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28809387

Group type: EXPERIMENTAL
Intervention: Cytosponge
Number of subjects: 80

Group type: COMPARATOR
Intervention: Endoscopy with biopsy
Number of subjects: 80
Study: 28810177

Group type: EXPERIMENTAL
Intervention: Second generation antipsychotic medications (SGAs)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Non-exposed women with psychiatric conditions
Number of subjects: 303
Study: 28810418

Group type: EXPERIMENTAL
Intervention: Culturally tailored cardiovascular disease prevention program
Number of subjects: 0
Study: 28810801

Group type: EXPERIMENTAL
Intervention: Fermented papaya preparation (FPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 0
Study: 28810837

Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg + Bevacizumab 7.5 mg/kg (DL1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg + Bevacizumab 7.5 mg/kg (DL2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg + Bevacizumab 10 mg/kg (DL3)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg + Bevacizumab 10 mg/kg (DL4)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pazopanib (400 mg and 600 mg) pharmacokinetics
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overall response to treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toxicity profile
Number of subjects: 25
Study: 28810904

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (AAD) - beta blockers (80.9% in previously diagnosed AF, 71.0% in newly diagnosed AF), calcium channel antagonists (24.0% in newly diagnosed AF).
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (AAD) - class I (11.4%) and class III (9.1%) AADs.
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Beta blockers as rate control therapy.
Number of subjects: 1013
Study: 28810925

Group type: EXPERIMENTAL
Intervention: Surgical IPP with melphalan 30 mg/m²
Number of subjects: 10

Group type: COMPARATOR
Intervention: Percutaneous IPP with melphalan 30 mg/m²
Number of subjects: 10
Study: 28812042

Group type: EXPERIMENTAL
Intervention: LaserACE procedure
Number of subjects: 26
Study: 28812172

Group type: EXPERIMENTAL
Intervention: Allogeneic acellular dermal matrix (ADM)
Number of subjects: 22
Study: 28812175

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emergency appendectomy
Number of subjects: 0
Study: 28813164

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for 24 months or until disease progression or intolerable toxicity.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 24
Study: 28814281

Group type: EXPERIMENTAL
Intervention: New generation hormone-therapy (NGHT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: First generation androgen deprivation therapy (Control)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (NGHT)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Enzalutamide (NGHT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Healthy participants (Control)
Number of subjects: 134
Study: 28814336

Group type: EXPERIMENTAL
Intervention: Shared injection drug solution
Number of subjects: 2150

Group type: EXPERIMENTAL
Intervention: Received used drug injection equipment
Number of subjects: 2150

Group type: COMPARATOR
Intervention: Shared solutions
Number of subjects: 2150

Group type: COMPARATOR
Intervention: Unsafe injection risk
Number of subjects: 2150

Group type: EXPERIMENTAL
Intervention: Injection risk behaviour
Number of subjects: 2150
Study: 28814396

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Micronutrient powder containing ferrous fumarate and sodium iron EDTA
Number of subjects: 0
Study: 28814412

Group type: EXPERIMENTAL
Intervention: Aflibercept 2.0 mg intravitreal injections
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aflibercept retreatment during ENDURANCE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Visual acuity and central retinal thickness
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Progression of diabetic retinopathy
Number of subjects: 60
Study: 28814432

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (unexposed similar-age infants)
Number of subjects: 17
Study: 28814660

Group type: EXPERIMENTAL
Intervention: ERT+ITI (rituximab, methotrexate, IVIG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: ERT monotherapy
Number of subjects: 19
Study: 28814674

Group type: EXPERIMENTAL
Intervention: Rilonacept (loading dose 4.4 mg/kg, followed by 2.2 mg/kg once weekly for 12 months, with dose escalation allowed)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 6
Study: 28815191

Group type: EXPERIMENTAL
Intervention: Eye rubbing for 2 minutes in one eye
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (fellow eye without rubbing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eye rubbing
Number of subjects: 0
Study: 28815476

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 6051
Study: 28815486

Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus (SA) carriage
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (MRSA) carriage
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Throat-only SA carriage
Number of subjects: 300
Study: 28815625

Group type: EXPERIMENTAL
Intervention: Unilateral neonatal arterial ischemic stroke (NAIS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 33
Study: 28815645

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/day orally on days 1-21 every 4 weeks
Number of subjects: 55
Study: 28815757

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Overall monitoring
Number of subjects: 1242
Study: 28817190

Group type: EXPERIMENTAL
Intervention: Filanesib (1.50 mg/m²) single agent
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Filanesib (1.50 mg/m²) plus dexamethasone (40 mg/week)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study: 28817727

Group type: EXPERIMENTAL
Intervention: Oral lithium carbonate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment including 2 mg/kg per day of prednisone equivalent
Number of subjects: 20
Study: 28817753

Group type: EXPERIMENTAL
Intervention: Durvalumab, 10 mg/kg every 2 weeks for up to 12 months
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Durvalumab, 10 mg/kg every 2 weeks
Number of subjects: 191
Study: 28817997

Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Number of subjects: 5148

Group type: EXPERIMENTAL
Intervention: Cladribine 5.25 mg/kg
Number of subjects: 5148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5148
Study: 28818050

Group type: EXPERIMENTAL
Intervention: Probiotic administration with Bifidobacterium animalis subsp. lactis (BB-12®) and Lactobacillus rhamnosus (LGG®) for 6 months
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Probiotic administration
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sub-analysis of gut microbiota with detected growth of probiotics
Number of subjects: 201
Study: 28818061

Group type: EXPERIMENTAL
Intervention: Longitudinal mean deviation (MD) and visual acuity (VA) from the Ocular Hypertension Treatment Study (OHTS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditional correlation given random effects
Number of subjects: 0
Study: 28818154

Group type: EXPERIMENTAL
Intervention: Physiology-based model incorporating selected variables as surrogates of anatomical and nonanatomical traits
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Multivariate regression using PSG parameters plus PSG-derived estimates of loop gain and arousal threshold
Number of subjects: 31

Group type: COMPARATOR
Intervention: Multiple regression based on PSG parameters alone
Number of subjects: 31
Study: 28818208

Group type: EXPERIMENTAL
Intervention: TTS-iPSC-CMs subjected to catecholamine stimulation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control iPSC-CMs (not explicitly detailed in the abstract)
Number of subjects: 2
Study: 28818221

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Venography
Number of subjects: 100
Study: 28818546

Group type: EXPERIMENTAL
Intervention: Glecaprevir (300 mg) plus Pibrentasvir (120 mg) once daily for 12 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Glecaprevir plus Pibrentasvir
Number of subjects: 146
Study: 28818863

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced cardiac magnetic resonance (CE-CMR) imaging
Number of subjects: 797

Group type: COMPARATOR
Intervention: Transthoracic echocardiography
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: CE-CMR imaging
Number of subjects: 797
Study: 28819385

Group type: EXPERIMENTAL
Intervention: Kanglaite Injection (KLTi) plus Gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 0
Study: 28819570

Group type: EXPERIMENTAL
Intervention: HCV Integrated Care (IC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 28819927

Group type: EXPERIMENTAL
Intervention: Delayed-release prednisone (DR-prednisone)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Immediate-release prednisone (IR-prednisone)
Number of subjects: 56
Study: 28819932

Group type: EXPERIMENTAL
Intervention: Twice-daily (BID) dosing of 0.075% bromfenac in DuraSite
Number of subjects: 85

Group type: COMPARATOR
Intervention: Once-daily (QD) dosing of 0.075% bromfenac in DuraSite
Number of subjects: 85
Study: 28820057

Group type: EXPERIMENTAL
Intervention: ACEIs
Number of subjects: 2683

Group type: EXPERIMENTAL
Intervention: ARBs
Number of subjects: 2683
Study: 28820303

Group type: EXPERIMENTAL
Intervention: Rapid Ventricular Pacing (RVP) applied in 16 patients, mean duration 60 ± 25 seconds, mean heart rate 173 ± 23 bpm, arterial pressure reduction to 35-55 mm Hg.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RVP
Number of subjects: 20
Study: 28820321

Group type: EXPERIMENTAL
Intervention: Whole-mouth ultrasonic debridement, scaling and root planing, and a 7-day prescription of amoxicillin and metronidazole
Number of subjects: 60
Study: 28820507

Group type: EXPERIMENTAL
Intervention: Patients with infection
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Patients with grade 2 or greater acute graft-versus-host disease (GVHD)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Patients with nonspousal caregivers
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 136
Study: 28821268

Group type: EXPERIMENTAL
Intervention: Extreme hypo-fractionated SBRT (5 fractions of 7 Gy)
Number of subjects: 85
Study: 28821470

Group type: EXPERIMENTAL
Intervention: Genoidentical hematopoietic stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic transfusion
Number of subjects: 0
Study: 28821473

Group type: EXPERIMENTAL
Intervention: Facebook intervention (private Facebook group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Handouts and email materials (comparison group)
Number of subjects: 60
Study: 28821985

Group type: EXPERIMENTAL
Intervention: Urinary samples processed with centrifugation prior to storage
Number of subjects: 19

Group type: COMPARATOR
Intervention: Urinary samples processed with centrifugation prior to analysis
Number of subjects: 19
Study: 28822437

Group type: EXPERIMENTAL
Intervention: Neonatal morbidities
Number of subjects: 0
Study: 28822957

Group type: EXPERIMENTAL
Intervention: 67 mcg/kg/day of recombinant human growth hormone (rhGH) for 2 years
Number of subjects: 19
Study: 28822985

Group type: EXPERIMENTAL
Intervention: Reticular pseudodrusen (RPD) detected in participants with CAD
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Intermediate age-related macular degeneration (AMD) features
Number of subjects: 534
Study: 28823554

Group type: EXPERIMENTAL
Intervention: MR-HIFU
Number of subjects: 9

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 9
Study: 28823829

Group type: COMPARATOR
Intervention: Strict-normal thyroid function (plasma TSH level 0.4 to 2.5 mIU/L)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (plasma TSH above 4.5 mIU/L)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Low-normal thyroid function (plasma TSH level 2.5 to 4.5 mIU/L)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Low thyroid function (subclinical hypothyroidism and low-normal thyroid function combined)
Number of subjects: 425
Study: 28824369

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg daily)
Number of subjects: 9
Study: 28824816

Group type: EXPERIMENTAL
Intervention: Kinect-based VR intervention using commercially available motion capture games
Number of subjects: 1
Study: 28824866

Group type: EXPERIMENTAL
Intervention: Pendant position
Number of subjects: 308

Group type: COMPARATOR
Intervention: Traditional sitting position
Number of subjects: 308
Study: 28825151

Group type: EXPERIMENTAL
Intervention: AMH level
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ESR2 and FSHR gene polymorphisms
Number of subjects: 216
Study: 28825603

Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet (SCD)
Number of subjects: 8
Study: 28826066

Group type: EXPERIMENTAL
Intervention: Acceptance-based interoceptive exposure treatment
Number of subjects: 24
Study: 28826087

Group type: EXPERIMENTAL
Intervention: Citalopram monotherapy
Number of subjects: 239
Study: 28826425

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28826699

Group type: EXPERIMENTAL
Intervention: Major surgery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Postprandial state after surgery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cancer group post-surgery
Number of subjects: 18
Study: 28827160

Group type: EXPERIMENTAL
Intervention: Short mobile messages (SMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28827212

Group type: EXPERIMENTAL
Intervention: Spanish version of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A), delivered as 9 sessions of 55 minutes each by advanced doctoral and masters students in clinical psychology.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Waitlist (WL) control group, receiving the intervention after the 3-month follow-up assessment.
Number of subjects: 152
Study: 28827369

Group type: EXPERIMENTAL
Intervention: Patients' stated values regarding end-of-life care
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Decisional conflict regarding life-support decisions
Number of subjects: 503
Study: 28827798

Group type: EXPERIMENTAL
Intervention: Learning Families Project intervention including promotion, resident training, and community activities (talks, day camp, thematic activities, horticulture class).
Number of subjects: 978

Group type: COMPARATOR
Intervention: Control group (Shun Tin Estate).
Number of subjects: 978
Study: 28828187

Group type: EXPERIMENTAL
Intervention: Eight-week exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28828390

Group type: EXPERIMENTAL
Intervention: Toric phakic intraocular lens (PIOL) implantation (TICL group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Combined astigmatic keratotomy (AK) and spherical PIOL implantation (AK + ICL group)
Number of subjects: 54
Study: 28828394

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 969

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 969
Study: 28828532

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 µg/kg)
Number of subjects: 0
Study: 28829523

Group type: EXPERIMENTAL
Intervention: Morphine intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 157
Study: 28829745

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffolds (BVS)
Number of subjects: 3231
Study: 28830448

Group type: EXPERIMENTAL
Intervention: Severe NAFLD
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 28830483

Group type: EXPERIMENTAL
Intervention: Multi-level pregnancy tests (MLPTs) at home for monitoring hCG trends after assisted reproductive technology (ART)
Number of subjects: 104
Study: 28830573

Group type: EXPERIMENTAL
Intervention: 94-SNP risk score
Number of subjects: 8703
Study: 28830854

Group type: EXPERIMENTAL
Intervention: PedAMINES (mobile device app)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional preparation methods (infusion rate table)
Number of subjects: 120
Study: 28830889

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28830912

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28830971

Group type: EXPERIMENTAL
Intervention: Solitaire Revascularization Device and Mindframe Capture Low Profile Revascularization Device
Number of subjects: 984
Study: 28830975

Group type: EXPERIMENTAL
Intervention: Inpatient Rehabilitation Facilities (IRF)
Number of subjects: 31775

Group type: COMPARATOR
Intervention: Skilled Nursing Facility (SNF)
Number of subjects: 31775

Group type: EXPERIMENTAL
Intervention: Hospital-level variation in discharge rates to IRF
Number of subjects: 31775

Group type: EXPERIMENTAL
Intervention: Hospital-level variation in discharge rates to IRF after adjustment
Number of subjects: 31775
Study: 28831208

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers assessment
Number of subjects: 2983
Study: 28832410

Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 806
Study: 28833465

Group type: EXPERIMENTAL
Intervention: Telephone interpreting service used by midwives during postnatal home visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus group discussions and semi-structured interviews with users in their own language (Albanian and Tigrinya)
Number of subjects: 0
Study: 28834316

Group type: EXPERIMENTAL
Intervention: History of B19V infection
Number of subjects: 958

Group type: COMPARATOR
Intervention: No prior B19V infection
Number of subjects: 958
Study: 28834619

Group type: EXPERIMENTAL
Intervention: High-dose benazepril (mean 69 mg/day, range 40-80)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: High-dose valsartan (mean 526 mg/day, range 320-640)
Number of subjects: 480

Group type: COMPARATOR
Intervention: High-dose valsartan
Number of subjects: 480

Group type: COMPARATOR
Intervention: Low-dose benazepril (20 mg/day)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Low-dose valsartan (160 mg/day)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Extended-release metoprolol (mean 152 mg/day, range 23.75-190)
Number of subjects: 480
Study: 28834623

Group type: EXPERIMENTAL
Intervention: HBV/HDV co-infected women giving birth to children
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: HBV DNA levels
Number of subjects: 742
Study: 28834795

Group type: EXPERIMENTAL
Intervention: Opioid-based anaesthesia induction
Number of subjects: 35
Study: 28835355

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 at a dose of 2×10^8 CFU
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 28835365

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no coffee consumption)
Number of subjects: 0
Study: 28835440

Group type: EXPERIMENTAL
Intervention: Treatment for chronic myeloid leukemia (CML)
Number of subjects: 0
Study: 28835521

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28835533

Group type: EXPERIMENTAL
Intervention: Self-anal examination (SAE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Partner anal examination (PAE)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Digital anorectal examination (DARE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall (SAE and PAE)
Number of subjects: 200
Study: 28835849

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 50
Study: 28836957

Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-3 mg/d)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Cariprazine (4.5-6 mg/d)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Cariprazine (9 mg/d)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Cariprazine (all doses)
Number of subjects: 679
Study: 28837210

Group type: EXPERIMENTAL
Intervention: Extended anticoagulation with vitamin K antagonists
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Clinical score based on seven clinical factors
Number of subjects: 743
Study: 28837404

Group type: EXPERIMENTAL
Intervention: HPV vaccine initiation in cancer survivors
Number of subjects: 982

Group type: COMPARATOR
Intervention: HPV vaccine initiation in general population
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: HPV vaccine initiation in adolescent survivors (ages 13 to 17 years)
Number of subjects: 982

Group type: COMPARATOR
Intervention: HPV vaccine initiation in adolescent peers (ages 13 to 17 years)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: HPV vaccine initiation in young adult survivors (ages 18 to 26 years)
Number of subjects: 982

Group type: COMPARATOR
Intervention: HPV vaccine initiation in young adult peers (ages 18 to 26 years)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - lack of provider recommendation
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - perceived lack of insurance coverage
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - male sex
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - endorsement of vaccine-related barriers
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - younger age (9 to 12 years)
Number of subjects: 982